NXTC, US65343E2072

NextCure stock faces a November court test over its reverse split

Published on 10/06/2026 at 13:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

NextCure stock faces a November 6 court hearing over its 1-for-12 reverse split. Q2 net loss narrowed to USD 14.892 million from USD 26.808 million.

NXTC, US65343E2072, Illustration mit AI erstellt.

NextCure stock (ISIN US65343E2072) was last at USD 5.05 on Nasdaq on October 5, 2026 at 4:00 p.m. ET, down 0.79 percent from the prior close. The immediate corporate issue is a Delaware court test over the company's 1-for-12 reverse split, which could affect its proposed combination with Avere Therapeutics.

Court review puts the merger in focus

According to StockTitan, NextCure disclosed on September 25, 2026 that it asked the Delaware Court of Chancery to validate the reverse split that became effective on July 14, 2025. The company said uncertainty over the applicable voting standard emerged after Delaware law changes took effect in August 2026.

The court scheduled a hearing for 3:00 p.m. ET on November 6, 2026. Written positions from stockholders are due by October 27, 2026, while NextCure said an unsuccessful petition could delay or prevent the proposed Avere business combination, according to StockTitan.

Quarterly loss narrows sharply

NextCure reported a USD 14.892 million net loss for Q2 2026, compared with USD 26.808 million in Q2 2025. Basic and diluted EPS improved to negative USD 2.80 from negative USD 11.29, while research and development expense fell to USD 7.425 million from USD 24.091 million, according to StockTitan.

Cash, cash equivalents and marketable securities totaled USD 20.088 million on June 30, 2026, down from USD 41.818 million on December 31, 2025. The balance sheet therefore remains closely tied to the timing and terms of the Avere transaction and any further financing.

Analyst target remains far above price

As of September 30, 2026, ToAlpha listed one analyst at Buy, with an average target of USD 20.00 and high and low targets also at USD 20.00. The target lies 296.0 percent above the USD 5.05 price used here, making the legal outcome and merger timetable more important than a standard earnings comparison.

NextCure stock stays near USD 5

NXTC's October 5, 2026 price of USD 5.05 stood within a USD 1.55 to USD 15.74 52-week range and came with a USD 18.2 million market capitalization. The next scheduled milestones are the shareholder submission deadline, the court hearing and the earnings date listed for October 29, 2026.